Ingrid A. Mayer

Oncology
719 Thompson Ln Ste 25000
Nashville, TN 37204

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 155 publications

Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.

Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.

Journal: JCO oncology practice
Published: July 21, 2026

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.

Journal: JCO oncology advances
Published: May 18, 2026

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts Anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2025

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

Journal: ESMO open
Published: October 07, 2025

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.

Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.

Journal: ESMO open
Published: August 21, 2025

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.

Journal: Future oncology (London, England)
Published: February 28, 2025

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.

A phase Ib/II trial of atezolizumab with cobimetinib or idasanutlin in metastatic estrogen receptor positive breast cancer.

Journal: NPJ breast cancer
Published: December 20, 2024

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 14, 2024

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.

Cigarette Smoking and Symptom Burden: Baseline Results From Nine ECOG-ACRIN Cancer Clinical Trials.

Journal: Journal of pain and symptom management
Published: October 08, 2024

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Journal: Research square
Published: May 15, 2024

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Journal: Breast cancer research and treatment
Published: April 19, 2024
Showing 1-12 of 155

Last Updated: 09/26/2026